Mackenzie Financial Corp Trims Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Mackenzie Financial Corp decreased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 3.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,331 shares of the company’s stock after selling 1,912 shares during the period. Mackenzie Financial Corp’s holdings in Hims & Hers Health were worth $439,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Pathstone Family Office LLC increased its stake in Hims & Hers Health by 2.8% in the third quarter. Pathstone Family Office LLC now owns 65,876 shares of the company’s stock worth $414,000 after purchasing an additional 1,824 shares during the period. Baldwin Brothers LLC MA increased its stake in Hims & Hers Health by 17.0% in the fourth quarter. Baldwin Brothers LLC MA now owns 22,128 shares of the company’s stock worth $197,000 after purchasing an additional 3,215 shares during the period. Arizona State Retirement System increased its stake in Hims & Hers Health by 9.6% in the third quarter. Arizona State Retirement System now owns 40,050 shares of the company’s stock worth $252,000 after purchasing an additional 3,520 shares during the period. Teacher Retirement System of Texas increased its stake in Hims & Hers Health by 7.4% in the third quarter. Teacher Retirement System of Texas now owns 72,253 shares of the company’s stock worth $454,000 after purchasing an additional 4,954 shares during the period. Finally, EMC Capital Management increased its stake in shares of Hims & Hers Health by 80.0% during the third quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after buying an additional 5,332 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $12.50 on Friday. The company has a market cap of $2.68 billion, a PE ratio of -113.64 and a beta of 0.91. The business has a 50-day simple moving average of $13.75 and a two-hundred day simple moving average of $10.05. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $17.16.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.03. The business had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company’s quarterly revenue was up 47.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.05) earnings per share. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 15,100 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $9.01, for a total value of $136,051.00. Following the completion of the sale, the chief executive officer now owns 51,653 shares of the company’s stock, valued at $465,393.53. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Oluyemi Okupe sold 31,363 shares of Hims & Hers Health stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $10.03, for a total transaction of $314,570.89. Following the completion of the sale, the chief financial officer now owns 156,721 shares of the company’s stock, valued at $1,571,911.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 15,100 shares of Hims & Hers Health stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $9.01, for a total value of $136,051.00. Following the sale, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at approximately $465,393.53. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 548,150 shares of company stock valued at $7,327,717. 31.63% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Leerink Partnrs restated a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Piper Sandler raised their price target on Hims & Hers Health from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Tuesday, February 27th. Jefferies Financial Group restated a “hold” rating and set a $15.00 price target (down previously from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. TheStreet upgraded Hims & Hers Health from a “d” rating to a “c” rating in a research note on Monday, March 4th. Finally, Imperial Capital upgraded Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target on the stock in a research note on Wednesday, February 28th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.85.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.